View in EDS

Safety of continuous nebulized albuterol for bronchospasm in infants and children.

Saved in:
Bibliographic Details
Title: Safety of continuous nebulized albuterol for bronchospasm in infants and children.
Authors: Katz RW (AUTHOR), Kelly HW (AUTHOR), Crowley MR (AUTHOR), Grad R (AUTHOR), McWilliams BC (AUTHOR), Murphy SJ (AUTHOR)
Source: Pediatrics. Nov93, Vol. 92 Issue 5, p666-669. 4p.
Abstract: OBJECTIVE. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. DESIGN. Prospective, case series. SETTING. A university pediatric intensive care and pediatric subacute units. PATIENTS. Nineteen infants and children who received CNA for at least 24 hours. INTERVENTIONS. None. MEASUREMENTS. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was > or = 250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. MAIN RESULTS. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. CONCLUSIONS. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined. [ABSTRACT FROM AUTHOR]
Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:OBJECTIVE. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. DESIGN. Prospective, case series. SETTING. A university pediatric intensive care and pediatric subacute units. PATIENTS. Nineteen infants and children who received CNA for at least 24 hours. INTERVENTIONS. None. MEASUREMENTS. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was > or = 250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. MAIN RESULTS. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. CONCLUSIONS. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined. [ABSTRACT FROM AUTHOR]
ISSN:00314005
DOI:10.1542/peds.92.5.666